Advanced Cell Technology, Inc.

Read the original here:
ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …

Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today that Phase 1/2 clinical data published in The Lancet as an early online publication demonstrate the safety of ACT’s human embryonic stem cell -derived retinal pigment epithelium cells for the treatment of Stargardt’s macular dystrophy and dry age-related macular degeneration .

Read more here:
ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients

Advanced Cell Technology, Inc. ;, a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelium derived from human embryonic stem cells .

Read the rest here:
ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe